- Home
- CYCN vs NCNA Comparison
CYCN vs NCNA Comparison
Compare CYCN & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- NCNA
- Stock Information
- Founded
- CYCN 2018
- NCNA 1997
- Country
- CYCN United States
- NCNA United Kingdom
- Employees
- CYCN N/A
- NCNA N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- CYCN Health Care
- NCNA Health Care
- Exchange
- CYCN Nasdaq
- NCNA Nasdaq
- Market Cap
- CYCN 7.6M
- NCNA 7.6M
- IPO Year
- CYCN N/A
- NCNA 2017
- Fundamental
- Price
- CYCN $1.41
- NCNA $3.72
- Analyst Decision
- CYCN
- NCNA
- Analyst Count
- CYCN 0
- NCNA 0
- Target Price
- CYCN N/A
- NCNA N/A
- AVG Volume (30 Days)
- CYCN 1.0M
- NCNA 210.6K
- Earning Date
- CYCN 11-07-2025
- NCNA 11-14-2025
- Dividend Yield
- CYCN N/A
- NCNA N/A
- EPS Growth
- CYCN N/A
- NCNA N/A
- EPS
- CYCN N/A
- NCNA N/A
- Revenue
- CYCN $2,174,000.00
- NCNA N/A
- Revenue This Year
- CYCN N/A
- NCNA N/A
- Revenue Next Year
- CYCN N/A
- NCNA N/A
- P/E Ratio
- CYCN N/A
- NCNA N/A
- Revenue Growth
- CYCN N/A
- NCNA N/A
- 52 Week Low
- CYCN $1.27
- NCNA $2.78
- 52 Week High
- CYCN $9.47
- NCNA $332.00
- Technical
- Relative Strength Index (RSI)
- CYCN 34.60
- NCNA 43.93
- Support Level
- CYCN $1.60
- NCNA $3.55
- Resistance Level
- CYCN $2.23
- NCNA $3.90
- Average True Range (ATR)
- CYCN 0.16
- NCNA 0.25
- MACD
- CYCN -0.03
- NCNA -0.05
- Stochastic Oscillator
- CYCN 2.41
- NCNA 28.24
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.